AprilBio is up 6% in early trading on the 28th. The move is seen as driven by analysis from the securities industry that the company merits attention ahead of clinical results scheduled for the first half of this year.
As of 9:52 a.m. on the 28th, on the KOSDAQ market, AprilBio is trading at 59,300 won, up 3,500 won (6.27%) from the previous session.
Han Song-hyeop, a researcher at Daishin Securities, said, "AprilBio has already proven the commercial viability of its platform by out-licensing (L/O) APB-A1 and APB-R3 to Lundbeck and Evommune, respectively, using its proprietary 'SAFA' platform," and noted, "The cumulative contract value secured through two deals in 2021 and 2024 amounts to about 1.2 trillion won."
He added, "Efficacy results in patients from the phase 2a trial of APB-R3 and the phase 1b trial of APB-A1 are expected to be announced in the first half," and predicted, "If meaningful data are produced, the market may re-evaluate the overall SAFA platform along with enhancing the value of each pipeline."